facebook button MyTACTIC: Multiple Cohort Solid Tumor Trial
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

MyTACTIC: Multiple Cohort Solid Tumor Trial

Sponsor: Genentech, Inc.

MyTACTIC (ML42439) is an open-label, phase 2 study evaluating targeted therapies in patients who have advanced solid tumors with genomic alterations or protein expression patterns predictive or response.

For patients with specific qualifying mutations in any of the following genes: ROS1, PIK3CA, ALK, PTEN, AKT1/2/3, High Tumor Mutational Burden, Microsatellite Instability High, Mismatch Repair Deficient, ERBB2/HER2 (mutation or amplification).

For more information please contact the clinical research department: 631-675-5075